Document is current
Any future updates will be listed below
-
Authors
Jacobsen, Eric D. https://orcid.org/0000-0003-3014-0023
Kim, Haesook T.
Jeter, Erin
Jacobson, Caron
Fisher, David C.
Armand, Philippe https://orcid.org/0000-0001-6098-1603
-
Funding
Funding for this research was provided by:
Otsuka Pharmaceutical
- License Information
-
More Information
Article History
Received: 10 February 2022
Revised: 23 June 2022
Accepted: 8 August 2022
First Online: 22 August 2022
Competing interests
: EDJ reports the following conflicts: Consultancy: Daiichi, Secura Bio, ADC Therapeutics, Bayer, Imbrium, Eisai, Merck; Research Funding: Beigene, Novartis, Janssen/Pharmacyclics; PA reports the following conflicts: Consultancy: Merck, Bristol-Meyers Squibb, ADC Therapeutics, Tessa, GenMab, C4, Enterome, Regeneron, Epizyme, Astra Zeneca, Genentech, Xencor; Research funding: Merck, BMS, Adaptive, Genentech, IGM, Kite Honoraria: Merck; CJ reports the following conflicts: Consultancy: Kite/Gilead, Novartis, Bristol-Meyers Squib/Celgene, Nkarta, Precision Biosciences, Bluebird bio, Epizyme, Abbvie, Lonza, Ipsen, Instill Bio; Research funding: Pfizer and Kite/Gilead. HTK, EJ, and DCF report no conflicts.
